---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-008062"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:26:42.892350+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BARDA selects Edesa's paridiprubart for U.S. government-funded Phase 2 ARDS trial

## Summary
- Paridiprubart (EB05) chosen by BARDA for a randomized, double-blind, placebo-controlled Phase 2 platform trial in all-cause ARDS.
- Prior Phase 2 study showed paridiprubart reduced mortality by 84% among critically ill COVID-19 ARDS patients.
- Edesa's ongoing Phase 3 study of paridiprubart in COVID-19 ARDS continues in Canada and the U.S.
- BARDA contract managed via PPD (Thermo Fisher); Edesa supplies drug product and technical support.
- Goal is to label paridiprubart as standard-of-care for all-cause ARDS, with biomarker sub-study to inform development.

## SEC filing metadata
- accession: 0001654954-24-008062
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495424008062/0001654954-24-008062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495424008062/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-008062
- JSON: https://secwatch.observer/filing/0001654954-24-008062.json
- Plain text: https://secwatch.observer/filing/0001654954-24-008062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.